Mesalamine, also known as mesalazine or 5-ASA, is a medication used to treat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease [1]. It works by reducing inflammation in the colon [2]. Delayed-release formulations are designed to deliver the active ingredient to specific parts of the digestive tract, often the colon, to maximize effectiveness and minimize systemic absorption [3].
How does mesalamine delayed-release work?
Delayed-release mesalamine tablets are formulated with a coating that resists dissolution in the acidic environment of the stomach and upper small intestine. This coating breaks down in the higher pH of the lower small intestine and colon, releasing mesalamine where it is needed most to combat inflammation [4]. Various technologies are used to achieve this delayed release, such as pH-dependent coatings or matrix systems [5].
What conditions are treated with mesalamine delayed-release?
Mesalamine delayed-release tablets are primarily prescribed for the induction and maintenance of remission in mild to moderate ulcerative colitis [6]. They can also be used in certain cases of Crohn's disease involving the colon [7].
What are the different types of mesalamine delayed-release formulations?
Mesalamine is available in several delayed-release formulations, including tablets, capsules, and suppositories, each designed for different delivery mechanisms and disease locations [8]. Different tablet formulations may utilize different coating technologies to achieve delayed release, influencing where in the gastrointestinal tract the medication is released [5].
When does mesalamine patent protection expire?
Patent information for mesalamine and its various formulations can be complex due to multiple patents covering different aspects, such as the active ingredient, manufacturing processes, and specific delivery systems. DrugPatentWatch.com tracks these patents and their expiry dates [9]. For specific delayed-release formulations, patent expiry will depend on the individual patent protecting that particular technology or product [9].
Who manufactures mesalamine delayed-release products?
Several pharmaceutical companies manufacture mesalamine delayed-release tablets. These include both brand-name and generic manufacturers. Examples of brand-name products include Apriso, Asacol HD, and Lialda, with generic versions also available from various companies [10].
What are the potential side effects of mesalamine delayed-release?
Common side effects of mesalamine delayed-release tablets can include headache, nausea, abdominal pain, and diarrhea [11]. Less common but more serious side effects may involve kidney problems, liver problems, or allergic reactions [12].
How does mesalamine compare to other IBD treatments?
Mesalamine is generally considered a first-line treatment for mild to moderate ulcerative colitis [6]. For more severe disease or Crohn's disease, other medications like corticosteroids, immunomodulators, or biologic therapies may be necessary [13]. The choice of treatment depends on the severity and location of the disease, as well as individual patient factors [14].
Are there alternative treatments for ulcerative colitis?
Alternative treatments for ulcerative colitis include other aminosalicylate formulations (like mesalamine enemas or suppositories), corticosteroids, immunomodulators (such as azathioprine or methotrexate), and biologic therapies (like infliximab, adalimumab, or vedolizumab) [13].
What is the cost of mesalamine delayed-release tablets?
The cost of mesalamine delayed-release tablets can vary significantly depending on whether a brand-name or generic product is used, insurance coverage, and pharmacy pricing [15]. Generic versions are typically less expensive than brand-name medications [10].
Can biosimilars be developed for mesalamine delayed-release?
Mesalamine is a small molecule drug, and therefore, biosimilars, which are analogous to generics for biologic drugs, are not applicable. Generic versions of mesalamine delayed-release tablets can be developed and marketed once patents expire and regulatory approval is obtained [16].
What are the clinical trial results for mesalamine delayed-release?
Clinical trials for mesalamine delayed-release formulations have demonstrated their efficacy in achieving and maintaining remission in patients with ulcerative colitis [6]. Studies often compare different formulations or compare mesalamine to placebo or other treatments to establish its therapeutic benefit and safety profile [17].
---
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK557860/
[2] https://www.nhs.uk/medicines/mesalazine/
[3] https://www.drugbank.ca/drugs/DB00320
[4] https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/delayed-release
[5] https://www.sciencedirect.com/topics/medicine-and-dentistry/delayed-release-formulations
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085013/
[7] https://www.crohnsandcolitis.org.uk/about-crohns-and-colitis/medication-information/mesalazine
[8] https://www.verywellhealth.com/mesalamine-for-ulcerative-colitis-5210107
[9] https://drugpatentwatch.com/
[10] https://www.goodrx.com/mesalamine
[11] https://www.mayoclinic.org/drugs-supplements/mesalamine-oral-route/side-effects/drg-20068830
[12] https://www.drugs.com/sfx/mesalamine-delayed-release-side-effects.html
[13] https://www.nhs.uk/conditions/ulcerative-colitis/treatment/
[14] https://www.crohnscollitis.org.uk/about-crohns-and-colitis/medical-info/medication-guide
[15] https://www.singlecare.com/prescription/mesalamine
[16] https://www.fda.gov/drugs/development-approval-process-drugs/what-drug-biosimilar
[17] https://pubmed.ncbi.nlm.nih.gov/22588492/